Clinical Trials Browser

Withdrawn × INDUSTRY × ixazomib × Clear all

NCT05183139 2022-05-03

US MM-7

Phase 4 Withdrawn

Multiple Myeloma

NCT03888534 2020-09-28

Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03608501 2020-01-14

IDEALL

Phase 2 Withdrawn

Multiple Myeloma